作者: DANIEL R. CIOCCA , LAURA M. VARGAS ROIG
DOI: 10.1210/EDRV-16-1-35
关键词:
摘要: I. Introduction THE idea to write this review began a number of years ago when one us (D.R.C.) was working in Dr. William L. McGuire's laboratory San Antonio, Texas,1 where we were involved the study estrogen receptor(s) (ER) and estrogen-regulated proteins breast cancer. At that time ER beginning be identified tissues not considered classic targets for estrogens. The reviewing literature on presence nontarget did prosper because there methodological problems could give false positives ER, such as those reported melanomas (1). However, at detected by ligand binding assays. More than 10 yr have passed has been improved with advent widespread use monoclonal antibodies against receptor protein. described numerous normal pathological using ligandbinding immunochemical In addition, also studied messeng...